ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells $555,000.00 in Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver sold 50,000 shares of ARS Pharmaceuticals stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $11.10, for a total transaction of $555,000.00. Following the transaction, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,334,840.60. This trade represents a 19.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Laura Shawver also recently made the following trade(s):

• On Monday, December 2nd, Laura Shawver sold 97,244 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.56, for a total transaction of $1,318,628.64.
• On Wednesday, December 4th, Laura Shawver sold 14,772 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $13.75, for a total transaction of $203,115.00.

ARS Pharmaceuticals Trading Up 0.8 %

SPRY stock opened at $11.43 on Thursday. The business’s 50-day moving average is $13.18 and its 200 day moving average is $12.67. ARS Pharmaceuticals, Inc. has a 12-month low of $5.68 and a 12-month high of $18.51. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -22.41 and a beta of 0.96.

Wall Street Analysts Forecast Growth

SPRY has been the subject of several recent analyst reports. Leerink Partners lifted their price target on ARS Pharmaceuticals from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Friday, September 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $30.00 price objective on shares of ARS Pharmaceuticals in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, ARS Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $24.00.

Institutional Trading of ARS Pharmaceuticals

Several large investors have recently made changes to their positions in the company. nVerses Capital LLC purchased a new position in ARS Pharmaceuticals in the 3rd quarter valued at $30,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after buying an additional 4,472 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of ARS Pharmaceuticals in the second quarter worth about $87,000. J.W. Cole Advisors Inc. boosted its position in ARS Pharmaceuticals by 10.8% during the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock worth $131,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Quarry LP purchased a new stake in ARS Pharmaceuticals during the 3rd quarter valued at about $174,000. 68.16% of the stock is currently owned by hedge funds and other institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.